Patent portfolio

AroCell’s technologies are protected by a broad and deep patent portfolio covering all major markets globally.

Our patents cover specific peptide sequences, antibodies and their use. As part of our business model we are actively seeking licensing partners to create mutually advantageous agreements. If you are interested in our technologies, please do not hesitate to contact AroCell.
 

Patent no.

Protection

Countries

Status

Expire date

1627230Method for use of antibody based test for the prediction of cancer relapse - all immuno assays against TK1DE, ES, FR, GB, IT, SEApproved2024
4668180Method for use of antibody based test for the prediction of cancer relapse - all immuno assays against TK1JPApproved2024
10551385Method for use of antibody based test for the prediction of cancer relapse - all immuno assays against TK1USApproved2024
8501419Unique peptide sequence and corresponding antibodies and their use in determination of tumor proliferation (and more); epitope aa 161-203USApproved2028
2164954Unique peptide sequence and corresponding antibodies and their use in determination of tumor proliferation (and more); epitope aa 161-203DE, FR, GB, IT, SEApproved2028
10100128Monoclonal antibodies and methods for their use; Ar-1, Ar-2 and Ar-3USApproved2034
Monoclonal antibodies and methods for their use; Ar-1, Ar-2 and Ar-3USPending2034
3083698Monoclonal antibodies and methods for their use; Ar-1DE, ES, FR, GB, IT, SEApproved2034
Monoclonal antibodies and methods for their use; Ar-2EPPending2034
105980407Monoclonal antibodies and methods for their use; Ar-1CNApproved2034
6715770Monoclonal antibodies and methods for their use; Ar-1, Ar-2 and Ar-3JPApproved2034
Predicting survival of prostate cancerSEPending2040
Respiratory infection detection and classification using TK1International (PCT) Pending2040